维生素 K 对膝骨关节炎预后的作用
The appropriate form and dosing of vitamin K to benefit relevant outcomes in knee osteoarthritis (OA) are not known. In intervention studies for conditions other than knee OA (e.g., prevention of cardiovascular disease), the most commonly used forms and doses include phylloquinone (vitamin K1; 1000µg or 500µg daily) or menaquinone-7 (MK-7 or vitamin K2; 300µg daily). However, whether these doses are adequate to increase vitamin K to levels that ameliorate risk of adverse OA outcomes is not known. Furthermore, although some studies suggest enhanced bioavailability of MK-7 over vitamin K1, as well as extra-hepatic effects, whether this is relevant for an older population with knee OA is not known,
The overall goal of this pilot randomized clinical trial (RCT) is to test different subtypes and doses of vitamin K supplementation in older adults with knee OA and to measure changes in relevant biochemical measures.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
Massachusetts
-
Boston、Massachusetts、美国、02118
- Boston Medical Center, Rheumatology Clinic
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Men ≥50 years old
- Women ≥60 years old
- Clinical diagnosis of knee OA by the treating rheumatologist
- English fluency
Exclusion Criteria:
- Anticoagulation use (including warfarin, dabigatran, rivaroxaban, apixaban)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Vitamin K1 500 µg
Participants randomized to this arm will take one Vitamin K1 500 µg pill daily for 4 weeks. |
One pill daily for 4 weeks.
其他名称:
|
|
实验性的:Vitamin K1 1000 µg
Participants randomized to this arm will take one Vitamin K1 1000 µg pill daily for 4 weeks. |
One pill daily for 4 weeks.
其他名称:
|
|
实验性的:Vitamin K2 (MK-7) 300 µg
Participants randomized to this arm will take one Vitamin K2 (MK-7) 300 µg pill daily for 4 weeks. |
One pill daily for 4 weeks.
其他名称:
|
|
安慰剂比较:Placebo
Participants randomized to this arm will take 1 placebo pill daily for 4 weeks. |
Placebo pill daily for 4 weeks.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in uncarboxylated matrix Gla protein (ucMGP) levels
大体时间:Baseline, 4 weeks
|
Plasma ucMGP levels will be measured from blood samples using an enzyme-linked immunoassay (ELISA). |
Baseline, 4 weeks
|
|
Change in phylloquinone levels
大体时间:Baseline, 4 weeks
|
Plasma phylloquinone will be measured using high-pressure liquid chromatography (HPLC). |
Baseline, 4 weeks
|
|
Sufficient phylloquinone levels
大体时间:Baseline, 4 weeks
|
Defined as the the proportion of participants achieving phylloquinone level of >1.0 nmol/L, which is the level achieved when adequate intakes are met. |
Baseline, 4 weeks
|
|
Change in menaquinone-7 (MK-7) levels
大体时间:Baseline, 4 weeks
|
Menaquinone-7 (MK-7) will be measured from blood samples using HPCL. |
Baseline, 4 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Study adherence
大体时间:4 weeks
|
Adherence wil be assessed by analyzing pill counts for each participant. |
4 weeks
|
|
Participant acceptability of intervention
大体时间:4 weeks
|
Participants will use a 5 point LIkert scale to rate acceptability of the overall study, the pill tste, gastrointestinal tolerance, burden, and blood collection. |
4 weeks
|
合作者和调查者
调查人员
- 首席研究员:Jean Liew, MD MS、Boston University Chobanian & Avedisian School of Medicine, Department of Rheumatology
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- H-44897
- K23AR082938 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.